WhiteSwell's eLym System Shows Promise in Acute Heart Failure Fluid Management Trial
核心洞察
WhiteSwell (搜索)'s eLym system demonstrated successful fluid removal in all 21 trial patients with acute decompensated heart failure (搜索), achieving an average weight loss of 10.7 pounds during hospitalization.
The FDA granted Breakthrough Device Designation to the eLym system and accepted it into the Total Product Lifecycle Advisory Program, marking significant regulatory advancement.
Trial results showed promising 90-day outcomes with only 9.5% heart failure rehospitalization rate and no deaths, while maintaining stable kidney function throughout treatment.
WhiteSwell (搜索) has reported encouraging clinical data from a trial of 21 patients treated with its innovative eLym system, a minimally invasive solution for fluid removal in acute decompensated heart failure (搜索) (ADHF) patients. The results, presented at the Technology and Heart Failure Therapeutics (THT) meeting in Boston, demonstrate significant progress in addressing a critical medical need.
Clinical Trial Results and Patient Outcomes
The expanded cohort study, building upon earlier six-month feasibility data from nine patients, showed successful device deployment in all 21 hospitalized participants. Patients receiving eLym therapy in conjunction with diuretic treatment experienced substantial clinical improvements. The mean weight reduction from baseline to hospital discharge was 10.7 pounds, with all patients showing weight loss and demonstrating reduced peripheral edema and orthopnea.
Notably, kidney function remained stable throughout the treatment period and through discharge, a crucial consideration in heart failure management. The safety profile proved favorable, with only one patient experiencing a serious procedure-, device-, or therapy-related adverse event, which was resolved before discharge.
Innovative Technology and Mechanism
The eLym system represents a novel approach to treating ADHF through a catheter-based intervention. Deployed in the left internal jugular and innominate veins near the thoracic duct's connection point, the system creates a low-pressure zone that enhances fluid drainage when used alongside intravenous diuretics (搜索). This mechanism specifically targets the overwhelmed lymphatic system's ability to remove excess interstitial fluid from tissues and organs.
Regulatory Advancement and Future Plans
The FDA's decision to grant Breakthrough Device Designation and accept the eLym system into its Total Product Lifecycle Advisory Program (TAP) marks significant regulatory progress. WhiteSwell (搜索) continues to expand its clinical trial sites and plans to initiate a randomized controlled trial across the United States, Canada, and Europe later this year.
Expert Perspectives
Dr. Jan Biegus, deputy scientific director at the Institute of Heart Diseases at Wroclaw Medical University (搜索) in Poland, emphasized the significance of the results: "The lymphatic system is believed to be critical in effectively removing excess fluid from the tissues and organs, yet can be dysfunctional in heart failure patients. The 90-day rehospitalization rate of 9.5% with no deaths is substantially better than rates we see with standard-of-care diuretics (搜索) alone."
Eamon Brady, WhiteSwell (搜索) CEO, expressed optimism about the technology's potential impact: "By supporting the lymphatic system to drain interstitial tissues and organs in conjunction with diuretic therapy, we hope to break the cycle of repeated heart failure hospitalizations for people with ADHF and improve patient outcomes."